VICTORIA, Dec. 1, 2014 /CNW/ - T-Bird Pharma Inc.
(TSXV:TPI) ("T-Bird" or the "Company"), a
pharmaceutical company focused on developing premium quality
medical marijuana products and a licensed producer ("LP") under the
Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), is pleased to announce
that Dr. Bin Huang has joined the Company as President and Chief
Operating Officer. Dr Huang joins the Company as a key
part of its growth and commercialization strategy.
Dr. Huang began her career as a Research Scientist with Allelix
Crop Technologies focusing on improving canola growth traits such
as yield and disease-tolerance. She has also worked at GMP
Securities as a Partner and top-ranked Biotech analyst. Dr
Huang's management experience includes serving as President &
CEO of Cytovax Biotechnologies Inc. and WEX Pharmaceuticals Inc.,
both of which were Canadian public companies engaged in the
development of pharmaceutical products. As CEO of WEX, Dr.
Huang led the clinical development of Tetrodotoxin for cancer pain
under the auspices of both the FDA and Health Canada, oversaw drug
manufacturing in Canada and
Asia, and secured commercial
agreements with pharma partners. With both WEX and Cytovax,
she was responsible for raising both private and public capital,
managing capital markets relationships and ensuring public company
compliance.
Dr. Huang received her Ph.D in Plant Cell Biology from the
University of East Anglia, UK, her
MBA from the University of Toronto and
her BSc in Plant Genetics from Wuhan University, China.
Noted Dr. Huang, "I am very excited to join a company that has a
strong foothold in this new and growing industry, and in particular
one that wants to bring a strong pharmaceutical approach to its
business. I am very impressed by how much the founding team
has accomplished in such a short period of time and in an extremely
cost effective manner. Capital efficiency and maintaining
margins will be paramount as Medical Marijuana companies go to
scale."
"I am very pleased to be able to attract someone with Bin's
skill set to join our growing team. Her operational
experience as a pharma executive having overseen the building and
operating of clean rooms, as well as clinical trials under both the
FDA and Health Canada will be invaluable as we scale up in 2015,"
said Rob Gagnon, CEO and
Founder. Added David Raffa, Chairman, "Bin brings a wealth of
experience to our team. Her combination of a PhD in plant
science and an MBA make her an excellent candidate for our company,
and her having worked both as a Life Sciences analyst and as CEO of
two publicly traded life science companies brings added capital
markets expertise. Her skills complement the skills of our existing
team."
Concurrent with her appointment, the Company is granting to Dr.
Huang 600,000 stock options at a price of $0.56 per share, vesting over three years.
Dr. Huang has also been appointed to the Board of Directors of
the Company replacing Chris Taylor,
the Company's CFO. Mr. Taylor will continue in his capacity
as CFO and Corporate Secretary of the Company.
About T-Bird and Thunderbird
T-Bird Pharma Inc. is the parent company of Thunderbird
Biomedical Inc., a wholly owned private subsidiary formed in
January, 2013. The principal activities of Thunderbird are
the production of marijuana from its Victoria, British Columbia production
facility, as regulated by the Marihuana for Medical Purposes
Regulations (Canada). Thunderbird obtained a
medical marijuana license to undertake the production of medical
marijuana in February 2014, being the
fifth company in Canada to obtain
such a license. Thunderbird was acquired by T-Bird in
September, 2013.
ON BEHALF OF THE BOARD
"Robert Gagnon"
CEO and Director
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements.
Forward-looking statements include, but are not limited to,
statements with respect to commercial operations, including
production and sales of medical marijuana, anticipated revenues,
projected size of market, quantities of future medical marijuana
production, completion of production facilities and other
information that is based on forecasts of future results, estimates
of amounts not yet determinable and assumptions of
management.
T-Bird Pharma Inc. (the "Company") does not intend, and
does not assume any obligation, to update these forward-looking
statements except as required by law. These forward-looking
statements involve risks and uncertainties relating to, among other
things, results of production and sale activities, the Company's
historical experience with medical marijuana operations, uninsured
risks, regulatory changes, availability of production facilities,
timeliness of government approvals and the granting of permits and
licenses, changes in prices, actual operating and financial
performance of facilities, equipment and processes relative to
specifications and expectations. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
SOURCE T-Bird Pharma Inc.